Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Despite the considerable efficacy observed when targeting a dispensable lineage antigen,
such as CD19 in B cell acute lymphoblastic leukaemia,, the broader applicability of adoptive …

Adoptive cell therapy (ACT) is a rapidly growing anti‐cancer strategy that has shown
promise in treating various cancer types. The concept of ACT involves activating patients' …

Patients with acute myeloid leukemia (AML) often achieve remission after allogeneic
hematopoietic cell transplantation (allo-HCT) but subsequently die of relapse driven by …

Single-cell and spatial multimodal technologies have propelled discoveries of the solid
tumor microenvironment (TME) molecular features and their correlation with clinical …

In the past decade, the emergence of chimeric antigen receptor (CAR) T-cell therapy has led
to a cellular immunotherapy revolution against various cancers. Although CAR-T cell …

Hematologic malignancies (HMs) pose a serious threat to patients' health and life, and the
five-year overall survival of HMs remains low. The lack of understanding of the pathogenesis …

Leukemia relapse is a major cause of death after allogeneic hematopoietic cell
transplantation (allo-HCT). We tested the potential of targeting T cell (Tc) immunoglobulin …

Acute Myeloid Leukemia (AML) is an aggressive myeloid malignancy associated with high
mortality rates (less than 30% 5-year survival). Despite advances in our understanding of the …